Journal article
Combination intravesical chemotherapy for non-muscle invasive bladder cancer (NMIBC) as first-line or rescue therapy: where do we stand Now?
Expert opinion on pharmacotherapy, Vol.25(2), pp.203-214
2024
DOI: 10.1080/14656566.2024.2310073
PMID: 38264853
Abstract
The combination of intravesical gemcitabine (Gem) with docetaxel (Doce) or with mitomycin C (MMC) has been used in the primary setting as an alternative to Bacillus Calmette-Guerin (BCG) to treat high-risk (HR) and intermediate-risk (IR) non-muscle invasive bladder cancer (NMIBC), as well in the rescue setting for patients in whom BCG has failed.
Efficacy and safety of Gem/Doce and Gem/MMC to treat NMIBC in BCG-naïve and failure settings.
In the BCG-naïve setting, Gem/Doce was the primary alternative combination therapy reported, with a weighted mean 12- and 24-month recurrence-free survival (RFS) of 79% and 77% for HR disease and 84% and 76% for IR disease, respectively. In the HR BCG-failure setting, the weighted mean 12- and 24-month RFS was 60% and 42% for Gem/Doce and 63% and 40% for Gem/MMC. While patients without BCG exposure and papillary disease only benefit the most from Gem/Doce, there is also reasonable efficacy in BCG refractory disease and CIS. Combination therapy is well-tolerated, with grade III toxicity reported in less than 1% of patients. Unlike single agent chemotherapy, intravesical Gem/Doce is considered effective and safe regardless of risk-stratification.
Details
- Title: Subtitle
- Combination intravesical chemotherapy for non-muscle invasive bladder cancer (NMIBC) as first-line or rescue therapy: where do we stand Now?
- Creators
- Mohamad Abou Chakra - Department of Urology, The University of Iowa Hospitals and Clinics, Iowa City, IA, USAVignesh T Packiam - Rutgers, The State University of New JerseyIgor Duquesne - Hôpital CochinMichael Peyromaure - Hôpital CochinIan M McElree - University of IowaMichael A O'Donnell - University of Iowa
- Resource Type
- Journal article
- Publication Details
- Expert opinion on pharmacotherapy, Vol.25(2), pp.203-214
- DOI
- 10.1080/14656566.2024.2310073
- PMID
- 38264853
- eISSN
- 1744-7666
- Grant note
- name: John and Carol Walter Family Foundation
- Language
- English
- Electronic publication date
- 01/24/2024
- Date published
- 2024
- Academic Unit
- Urology
- Record Identifier
- 9984548666002771
Metrics
5 Record Views